SEC Form SC 13G/A filed by MannKind Corporation (Amendment)
$MNKD
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/27/2026 | $3.50 | Outperform → Sector Perform | RBC Capital Mkts |
| 11/24/2025 | Buy | Truist | |
| 11/13/2025 | $7.00 | Outperform | Leerink Partners |
| 10/20/2025 | $10.00 | Overweight | Wells Fargo |
| 10/10/2025 | $9.00 | Outperform | Leerink Partners |
| 7/16/2025 | $9.00 | Buy | H.C. Wainwright |
| 4/10/2025 | $12.00 | Outperform | Mizuho |
| 2/10/2025 | $11.00 | Outperform | Wedbush |
Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and support its progression into mid-stage clinica
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions
Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumpsApproval is supported by results from the Phase 3 INHALE-1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere® inhaled insulin developmentEligible patients can access Afrezza today for $35 or less per month, with
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
8-K - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
RBC Capital Mkts downgraded Mannkind from Outperform to Sector Perform and set a new price target of $3.50
Truist initiated coverage of Mannkind with a rating of Buy
Leerink Partners initiated coverage of Mannkind with a rating of Outperform and set a new price target of $7.00
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions
Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program updates: Afrezza® pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026Nintedanib DPI (MNKD-201) for IPF advancing into Phase 2; INFLO-2 trial anticipates enrolling first patient in Q2 2026Ralinepag DPI (MNKD-1501) announced as collaboration program with United Therapeutics, received additional $5M to support accelerated development Conference call and webcast today at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast beginning at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)